Actively Recruiting
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Led by Kahr Bio Australia Pty Ltd · Updated on 2026-04-09
90
Participants Needed
16
Research Sites
67 weeks
Total Duration
On this page
Sponsors
K
Kahr Bio Australia Pty Ltd
Lead Sponsor
N
Novotech (Australia) Pty Limited
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.
CONDITIONS
Official Title
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older with a life expectancy greater than 3 months
- Histologically confirmed inoperable MSS and/or pMMR colorectal cancer that has progressed on or is intolerant to specified therapies
- Received no more than 3 prior lines of therapy for colorectal cancer
- Measurable disease according to RECIST v1.1 criteria
You will not qualify if you...
- Presence of central nervous system metastases unless stable for 2 months after treatment with steroids
- Unresolved adverse events of Grade 2 or higher from prior cancer treatments
- Past or current autoimmune disease or immune deficiency
- History of another cancer within 3 years before starting the study treatment
- Current or recent treatment with certain anticancer therapies, CYP3A4 modulators, or immunomodulating therapies (except prior checkpoint inhibitors)
- Known allergy or hypersensitivity to study drugs or materials
- Clinically significant abnormal laboratory safety tests
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
University of Colarodo Cancer Center
Aurora, Colorado, United States, 80045
Not Yet Recruiting
2
Mayo Clinic
Florida City, Florida, United States, 32224
Not Yet Recruiting
3
Duke University Medical Center - Duke Cancer Center
Durham, North Carolina, United States, 27710
Actively Recruiting
4
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
5
The University of Texas MD Anderson Cancer Center
Texas City, Texas, United States, 77030
Not Yet Recruiting
6
The Queen Elizabeth Hospital
Woodville, Adelaide, Australia, 5011
Actively Recruiting
7
Chris O'brien Lifehouse
Camperdown, New South Wales, Australia, 2050
Actively Recruiting
8
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Actively Recruiting
9
Icon Cancer Centre
South Brisbane, Queensland, Australia, 4101
Actively Recruiting
10
Flinders Medical Centre SA
Bedford Park, South Australia, Australia, 5042
Actively Recruiting
11
Monash Health
Clayton, Victoria, Australia, 3168
Actively Recruiting
12
Footscray Hospital - Western Health
Footscray, Victoria, Australia, 3011
Actively Recruiting
13
Austin Health
Heidelberg, Victoria, Australia, 3084
Actively Recruiting
14
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Actively Recruiting
15
Sunshine Hospital - Western Health
Saint Albans, Victoria, Australia, 3021
Actively Recruiting
16
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia, 6009
Actively Recruiting
Research Team
A
Adam Foley Comer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here